FY2028 EPS Estimates for Novavax Cut by Zacks Research

Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at Zacks Research dropped their FY2028 earnings per share estimates for shares of Novavax in a research note issued on Wednesday, April 22nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.78 per share for the year, down from their previous estimate of $0.92. The consensus estimate for Novavax’s current full-year earnings is ($0.06) per share.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings upgraded shares of Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, March 12th. B. Riley Financial reiterated a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Finally, HC Wainwright increased their price target on Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.88.

Novavax Price Performance

Novavax stock opened at $8.15 on Friday. Novavax has a one year low of $5.80 and a one year high of $11.97. The business’s fifty day moving average is $9.16 and its 200 day moving average is $8.23. The stock has a market capitalization of $1.33 billion, a PE ratio of 3.38 and a beta of 2.65.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.77. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The business had revenue of $136.40 million during the quarter, compared to analyst estimates of $90.26 million. During the same quarter last year, the company earned ($0.51) EPS. The company’s quarterly revenue was up 66.6% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in Novavax during the third quarter valued at approximately $33,000. Flagship Harbor Advisors LLC bought a new position in Novavax in the 4th quarter worth $33,000. Danske Bank A S bought a new stake in Novavax during the third quarter valued at about $64,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,617 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Novavax in the second quarter worth about $52,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.